Jerry C. Griffin - 05 Jun 2023 Form 4 Insider Report for Inspire Medical Systems, Inc. (INSP)

Role
Director
Signature
/s/ Bryan Phillips, as Attorney-in-Fact for Jerry C. Griffin
Issuer symbol
INSP
Transactions as of
05 Jun 2023
Net transactions value
-$145,710
Form type
4
Filing time
07 Jun 2023, 17:57:41 UTC
Previous filing
01 Jun 2023
Next filing
14 Jun 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction INSP Common Stock Options Exercise $16,000 +1,000 +22% $16.00 5,613 05 Jun 2023 Direct
transaction INSP Common Stock Sale $8,865 -29 -0.52% $305.69 5,584 05 Jun 2023 Direct F1
transaction INSP Common Stock Sale $152,845 -500 -9% $305.69 5,084 05 Jun 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction INSP Stock Option (Right to Buy) Options Exercise $0 -1,000 -7.5% $0.000000 12,296 05 Jun 2023 Common Stock 1,000 $16.00 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Reflects shares sold to cover taxes upon the option exercise pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
F2 The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
F3 The option is fully vested and exercisable.